Guardion Health Sciences GHSI Stock News

Guardion Health Sciences Inc (NASDAQ: GHSI) is making a run for the top in the market this morning, gaining more than 30% early on. The gains come after the company announced a new product launch. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GHSI Stock Climbs On Product Launch

In a press release issued early this morning, Guardion Health Sciences said that it has completed the development of its CSV-2000 standardized contrast sensitivity test. The test will be introduced as a commercial product at Vision Expo West.

Vision Expo West is a conference that’s centered around ophthalmic professionals, which will be held in Las Vegas, Nevada.

At the moment, the CSV-2000 is the only computer-generated vision testing instrument available. GHSI said that it will provide the optical marketplace with its proprietary, industry-standard contrast sensitivity test, as well as a full suite of standard vision testing protocols.

The technology that creates a foundation for the product is known as AcQviz and is covered by strong patent protection. The technology automatically and constantly measures and adjustes screen luminance to a fixed standard light level for vision testing.

In a statement, Michael Favish, CEO at GHSI, had the following to offer:

The VectorVision CSV-2000 represents a paradigm shift in the accuracy and consistency of vision testing. This technology will allow doctors to more accurately and consistently quantify when treatment is needed and then document outcomes related to various therapies. The introduction of this technology extends Guardion’s leadership in the diagnosis and monitoring of vision changes related to eye disease.

Why This Is Exciting

The truth of the matter is that vision testing as it stands today is riddled with inaccuracies. The new CVS-2000 product will assist in lightening the load of these inaccuracies, making it a product that is likely to be in high demand in the optical medicine space.

After all, higher accuracy means that physicians will have the ability to provide better treatments to their patients.

Moreover, the new product launch expands on the ability of GHSI to generate revenue. After all, the product isn’t going to have $0 on the price tag. So, with a new revenue stream and a product that’s likely to be in high demand, investors have good reason to be excited here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.